Navigation Links
Dracen announces two DRP-104 presentations at AACR
Date:6/23/2020

Dracen Pharmaceuticals Inc., announced today that two posters profiling its lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association for Cancer Research Virtual meeting. One poster describes the immuno-metabolism and anti-cancer effects of DRP-104; and, the other profiles the potent, consistent single agent activity in KEAP1 mutant tumor models of NSCLC.

“As our lead asset DRP-104 advances in phase I clinical development, our preclinical data continues to confirm its promising profile both as a single agent and in combination therapy” said Robert Wild, Ph.D. Chief Scientific Officer of Dracen Pharmaceuticals. “The data being presented at AACR demonstrates that DRP-104 has a significant direct effect on tumors as well as profound remodeling of the tumor microenvironment; the latter leading to stimulation of both the innate as well as the adaptive immune systems resulting in therapeutic synergy with checkpoint inhibitors. Additionally, DRP-104 has demonstrated potent and broad antitumor activity in both murine and patient derived lung adenocarcinoma and squamous tumor models with KEAP1 mutations. The data suggests that DRP-104 is a promising therapy to treat KEAP1 mutant lung cancers and we are excited about advancing this promising compound in the clinic.”

The presentation details are as follows:

Broad Acting Glutamine Antagonism Remodels the Tumor Microenvironment; Induces Distinctive Immune Modulation; and, Synergizes with Immune Checkpoint Blockade
Abstract Date: June 22nd at 9:00 am - 6:00 pm
Abstract ID: 5607

Uncovering metabolic bottlenecks in KEAP1 mutant lung cancer
Abstract Date: June 22nd at 9:00 am - 6:00 pm
Abstract ID: 2569

About DRP-104
Our lead glutamine antagonist, DRP -104, is currently in early stage clinical development. The mechanisms of action for DRP-104 include: a) direct inhibition of tumor cell addiction to glutamine leading to substantial single agent activity and tumor regression; b) broad metabolic remodeling of the tumor microenvironment leading to enhanced anti-tumor immune activity; and, c) stimulation of T effector, NK and NKT cells and inhibition of immunosuppressive MDSC and macrophage cells, leading to greater long-term durable responses and survival.

About Dracen Pharmaceuticals
Dracen Pharmaceuticals, Inc. is a privately held biotech company developing proprietary anti-cancer drugs that target immuno-metabolism. Dracen’s investors include Deerfield Management; Osage University Partners; and The Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague). Dracen is headquartered in New York, NY with research operations in San Diego, CA.

Read the full story at https://www.prweb.com/releases/dracen_announces_two_drp_104_presentations_at_aacr/prweb17206686.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Panic Disorder
2. DuPont Nutrition & Biosciences Announces New Distribution Partnership with Interdisp JCS
3. Ripple Science Announces Initiatives for Clinical Research Teams During COVID
4. Lifecycle Biotechnologies Announces Investment in a Biotechnology Campus in Cleburne, Texas
5. Nutrition21 Announces the Adoption of CertainT® - a Technology That Protects the Dietary Supplement Industry and Consumers
6. R3 Medical Training Announces Next Comprehensive Stem Cell Training Course Set for March 13-14 2020 in Las Vegas
7. Shoreline Biome Announces New Asian Distribution Partnership
8. Sierra Announces NEW Line of MEMS-Based Thermal Mass Flow Controllers & Flow Meters
9. Brilliant Announces Partnership with WAVE Electronics to Offer Turnkey Smart Home Packages for Homebuilders and Multifamily Developers/Operators
10. QCDx Announces Sale of the RareScope to the Carole and Ray Neag Comprehensive Cancer Center at UConn Health for Use in Clinical Research
11. Vuja De Sciences Announces the Appointment of Two New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter maintenance and ... successful study, while protecting and accessing the catheter or device post-surgery is often undervalued ... Envigo in a live webinar on Wednesday, August 5, 2020 at ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... the early detection and prevention of high-burden diseases, and Centric Consulting, a business ... healthcare organizations to utilize existing data in order to identify and prioritize patients ...
(Date:7/10/2020)... ... 08, 2020 , ... Bode Technology, a leading ... operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical ... provides a turnkey solution that includes a comprehensive collection and virus-management program ...
(Date:7/10/2020)... (PRWEB) , ... July 09, 2020 , ... ... called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in zebrafish embryos, ... PolyU research team led by Dr MA has been using the zebrafish model ...
Breaking Biology Technology:
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today announced ... the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department ... scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement ...
(Date:7/10/2020)... Va. (PRWEB) , ... July 08, 2020 , ... ... Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, ... need a comparability study, but what is the most effective way to complete ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in ... Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide ...
Breaking Biology News(10 mins):